Chinese researchers reported engineering a compact CRISPR protein system designed to silence genes without cutting DNA, and packaged the approach into a single adeno-associated virus (AAV) vector. The platform uses epigenetic silencing principles, aiming to reduce the risks associated with DNA cleavage while keeping the payload size manageable for in vivo delivery. The work’s HBV relevance is a direct test of whether non-nuclease CRISPR approaches can work under the constraints of viral vector capacity and target biology. If the system continues to show durability and safety in relevant models, it could support a new wave of gene-silencing therapeutics for chronic viral infections. For developers, the key takeaway is the combination of a smaller CRISPR effector with a single-vector design, addressing one of the most common bottlenecks for CRISPR payload delivery.